Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non‐invasive detection of clinical biomarkers, potentially obviating the need for tissue biopsy, today announced new positive data recently presented at the ASCO 2016 Genitourinary Cancers Symposium (January 7‐9, San Francisco, California). These data from a prospective clinical study add to a growing body of clinical validation evidence demonstrating ExoDx™ Prostate(IntelliScore), the company’s completely non‐invasive urinebased liquid biopsy for prostate cancer, has the unique ability to accurately identify high‐grade prostate cancer (HGPCA) both at the time of biopsy and at surgery. These data demonstrate the potential for this first‐in‐class exosomal RNA (exoRNA)‐based assay to be utilized throughout the care continuum, including prior to initial biopsy, as well as for sequential monitoring of disease progression in patients enrolled in active surveillance.